RU2433997C2 - Ингибиторы цитозольной фосфолипазы a2 - Google Patents

Ингибиторы цитозольной фосфолипазы a2 Download PDF

Info

Publication number
RU2433997C2
RU2433997C2 RU2007140910/04A RU2007140910A RU2433997C2 RU 2433997 C2 RU2433997 C2 RU 2433997C2 RU 2007140910/04 A RU2007140910/04 A RU 2007140910/04A RU 2007140910 A RU2007140910 A RU 2007140910A RU 2433997 C2 RU2433997 C2 RU 2433997C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
ethyl
acceptable salt
compound
inhibitors
Prior art date
Application number
RU2007140910/04A
Other languages
English (en)
Other versions
RU2007140910A (ru
Inventor
Джон С. МАККЬЮ (US)
Джон С. МАККЬЮ
Катрин Л. ЛИ (US)
Катрин Л. ЛИ
Лилхрен ЧЕН (US)
Лилхрен ЧЕН
Ричард ВАРГАС (US)
Ричард Варгас
Джеймс Д. КЛАРК (US)
Джеймс Д. Кларк
Кара УИЛЬЯМС (US)
Кара УИЛЬЯМС
Валери КЛЕРИН (US)
Валери Клерин
Сюзана МАРУСИК (US)
Сюзана Марусик
Кевин ПОНГ (US)
Кевин Понг
Original Assignee
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайет filed Critical Вайет
Publication of RU2007140910A publication Critical patent/RU2007140910A/ru
Application granted granted Critical
Publication of RU2433997C2 publication Critical patent/RU2433997C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к 3-{4-[(2-{5-хлор-1-(дифенилметил)-2-[2-({[2-(трифторметил)бензил]сульфонил}амино)этил]-1Н-индол-3-ил}этил)сульфонил]фенил}пропионовой кислоте или ее фармацевтически приемлемой соли, которое ингибирует цитозольную фосфолипазу А2 (цФЛА2), что позволяет использовать его при лечении астмы. 3 н.п. ф-лы, 2 табл., 5 ил.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121

Claims (3)

1. Соединение, представляющее собой 3-{4-[(2-{5-хлор-1-(дифенилметил)-2-[2-({[2-(трифторметил)бензил]сульфонил}амино)этил]-1Н-индол-3-ил}этил)сульфонил]фенил}пропионовой кислоты или фармацевтически приемлемая соль указанного соединения.
2. Фармацевтическая композиция, ингибирующая цитозольную фосфолипазу А2 (цФЛА2), содержащая соединение по п.1 или его фармацевтически приемлемую соль и фармацевтически приемлемый носитель.
3. Способ лечения астмы у млекопитающего, включающий введение млекопитающему, нуждающемуся в лечении, фармацевтически приемлемого количества соединения по п.1 или его фармацевтически приемлемой соли.
RU2007140910/04A 2005-05-27 2006-05-26 Ингибиторы цитозольной фосфолипазы a2 RU2433997C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68556405P 2005-05-27 2005-05-27
US60/685,564 2005-05-27

Publications (2)

Publication Number Publication Date
RU2007140910A RU2007140910A (ru) 2009-07-10
RU2433997C2 true RU2433997C2 (ru) 2011-11-20

Family

ID=37188759

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007140910/04A RU2433997C2 (ru) 2005-05-27 2006-05-26 Ингибиторы цитозольной фосфолипазы a2

Country Status (33)

Country Link
US (3) US7557135B2 (ru)
EP (2) EP1891006B1 (ru)
JP (1) JP5116666B2 (ru)
KR (1) KR101353982B1 (ru)
CN (2) CN101184729B (ru)
AR (1) AR054195A1 (ru)
AT (1) ATE489364T1 (ru)
AU (1) AU2006251946B2 (ru)
BR (1) BRPI0610049A2 (ru)
CA (1) CA2607857C (ru)
CR (1) CR9520A (ru)
CY (1) CY1111151T1 (ru)
DE (1) DE602006018451D1 (ru)
DK (1) DK1891006T3 (ru)
ES (1) ES2354908T3 (ru)
GT (1) GT200600228A (ru)
HK (2) HK1113680A1 (ru)
HN (1) HN2006019513A (ru)
IL (1) IL186912A (ru)
MX (1) MX2007014589A (ru)
MY (1) MY144672A (ru)
NI (1) NI200700287A (ru)
NO (1) NO20075627L (ru)
NZ (1) NZ563736A (ru)
PE (1) PE20061426A1 (ru)
PL (1) PL1891006T3 (ru)
PT (1) PT1891006E (ru)
RU (1) RU2433997C2 (ru)
SI (1) SI1891006T1 (ru)
SV (1) SV2008002551A (ru)
TW (1) TW200718687A (ru)
UA (1) UA91053C2 (ru)
WO (1) WO2006128142A2 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
HN2004000536A (es) 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
IL161579A0 (en) 2004-04-22 2004-09-27 Mor Research Applic Ltd ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
WO2005115405A1 (en) 2004-04-28 2005-12-08 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
IL178401A (en) 2006-09-28 2012-04-30 Univ Ben Gurion Use of antisense oligonucleotides against 2 cPLA in the treatment of cancer
BRPI0718042A2 (pt) * 2006-10-31 2013-11-12 Wyeth Corp Formulações semissólidas de inibidores de enzima fosfolipase
JP2010508302A (ja) * 2006-10-31 2010-03-18 ワイス エルエルシー ホスホリパーゼ酵素の阻害剤の液剤
RU2009139931A (ru) 2007-03-29 2011-05-10 Асубио Фарма Ко., Лтд. (Jp) Производные индола, обладающие ингибирующей активностью в отношении сpla2, и способы их получения
US9526707B2 (en) 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
ES2611150T3 (es) * 2010-06-18 2017-05-05 The Whitehead Institute For Biomedical Research PLA2G16 como diana para compuestos antivirales
US20130209403A1 (en) 2010-09-08 2013-08-15 Ruprecht-Karls-Universitaet Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
GB201401904D0 (en) 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
US9815768B2 (en) 2014-02-28 2017-11-14 Sumitomo Chemical Company, Limited Method for producing 2-(halogenomethyl)-3-methylnitrobenzene
CN103804150A (zh) * 2014-03-01 2014-05-21 江苏斯威森生物医药工程研究中心有限公司 一种3,4-二甲氧基苄基溴的制备方法
CN108017522B (zh) * 2017-11-16 2021-01-05 贵州大学 一种2,6-二溴苯甲磺酰氯的制备工艺
PL424613A1 (pl) 2018-02-16 2019-08-26 Paweł Wawrzyński Rower dwukołowy o zmiennej konfiguracji
US20220220482A1 (en) * 2019-05-20 2022-07-14 Saint Louis University Reprogramming of lipid metabolism to inhibit t cell senescence and enhance tumor immunotherapy
CN115397824A (zh) * 2020-04-02 2022-11-25 吉利德科学公司 用于制备cot抑制剂化合物的方法
US20230338529A1 (en) * 2020-08-06 2023-10-26 The Children's Medical Center Corporation Compositions for altering a microglial cell, and methods of use therefore

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH48411A (fr) 1909-07-19 1910-10-17 Stephen Alley Outillage pour mettre en place et enlever les bandages élastiques des roues de véhicules
GB1148908A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Indole derivatives and processes for making them
FR1492929A (fr) 1966-05-11 1967-08-25 Roussel Uclaf Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (de) 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4271263A (en) * 1980-05-15 1981-06-02 Minnesota Mining And Manufacturing Company Thermally developable photosensitive compositions containing acutance agents
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4654360A (en) * 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
ES2045420T3 (es) 1988-04-13 1994-01-16 Ici America Inc Amidas ciclicas.
GB8906032D0 (en) 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
US5166170A (en) * 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5229516A (en) * 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
DK0640080T3 (da) 1992-05-13 1998-05-25 Syntex Inc Substituerede indoler som angiotensin II antagonister
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
DE59711058D1 (de) 1996-08-01 2004-01-08 Merckle Gmbh Acylpyrroldicarbonsäuren und acylindoldicarbonsäuren sowie ihre derivate als hemmstoffe der cytosolischen phospholipase a2
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
TR200002445T2 (tr) 1998-02-25 2000-12-21 Genetics Institute, Inc. Fosfolipaz inhibitörleri.
HUP0101146A3 (en) * 1998-02-25 2001-11-28 Genetics Inst Llc Cambridge Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
BR9908280A (pt) 1998-02-25 2000-10-31 Genetics Inst Inibidores de enzimas de fosfolipase
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6424105B1 (en) 1999-06-08 2002-07-23 Camco International, Inc. Real-time control of feedback signals to a motor for optimum performance
KR20020086665A (ko) * 2001-01-22 2002-11-18 소니 가부시끼 가이샤 용제 흡수성 수지 및 그 제조 방법
ES2300490T3 (es) * 2001-12-03 2008-06-16 Wyeth Inhibidores de fosfolipasa a2 citosolica.
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6635771B2 (en) * 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US6797708B2 (en) * 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
US6984735B2 (en) * 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7439249B2 (en) * 2002-12-31 2008-10-21 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
AU2003300114B9 (en) 2002-12-31 2009-11-26 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) * 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
WO2005023201A2 (en) 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
HN2004000536A (es) 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
GT200600228A (es) 2005-05-27 2006-12-26 Inhibidores de la fosfolipasa a2 citosolica
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clark J.D. et al.: «Potential therapeutic uses of phospholipase А2 inhibitors». EXPERT OPINION ON THERAPEUTIC PATENTS, v.l4, n.7, 2004, p.937-950. *

Also Published As

Publication number Publication date
AU2006251946B2 (en) 2011-05-12
CN101184729B (zh) 2011-02-16
AU2006251946A1 (en) 2006-11-30
HK1152710A1 (en) 2012-03-09
ES2354908T3 (es) 2011-03-21
US20070004719A1 (en) 2007-01-04
US20100022536A1 (en) 2010-01-28
IL186912A (en) 2012-05-31
CR9520A (es) 2008-02-20
WO2006128142A2 (en) 2006-11-30
NZ563736A (en) 2010-11-26
PL1891006T3 (pl) 2011-05-31
JP5116666B2 (ja) 2013-01-09
DE602006018451D1 (de) 2011-01-05
JP2008542303A (ja) 2008-11-27
IL186912A0 (en) 2008-02-09
MY144672A (en) 2011-10-31
MX2007014589A (es) 2008-01-21
TW200718687A (en) 2007-05-16
EP2248801A1 (en) 2010-11-10
US8283373B2 (en) 2012-10-09
GT200600228A (es) 2006-12-26
CA2607857C (en) 2014-02-11
KR20080021618A (ko) 2008-03-07
PT1891006E (pt) 2011-01-26
US20100029645A1 (en) 2010-02-04
CA2607857A1 (en) 2006-11-30
WO2006128142A8 (en) 2007-12-27
US7557135B2 (en) 2009-07-07
EP1891006B1 (en) 2010-11-24
PE20061426A1 (es) 2007-01-24
CY1111151T1 (el) 2015-06-11
DK1891006T3 (da) 2011-01-24
NI200700287A (es) 2008-05-27
HN2006019513A (es) 2011-03-02
BRPI0610049A2 (pt) 2010-05-25
CN102040550A (zh) 2011-05-04
AR054195A1 (es) 2007-06-06
NO20075627L (no) 2008-01-03
SV2008002551A (es) 2008-07-23
SI1891006T1 (sl) 2011-02-28
UA91053C2 (en) 2010-06-25
RU2007140910A (ru) 2009-07-10
CN101184729A (zh) 2008-05-21
CN102040550B (zh) 2012-10-03
HK1113680A1 (en) 2008-10-10
KR101353982B1 (ko) 2014-02-18
EP1891006A2 (en) 2008-02-27
ATE489364T1 (de) 2010-12-15
WO2006128142A3 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
RU2433997C2 (ru) Ингибиторы цитозольной фосфолипазы a2
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
EA200800791A1 (ru) Сульфонилпирролгидрохлориды, как ингибиторы гистондезацетилазы
RU2311200C2 (ru) Комбинация ингибитора циклооксигеназы-2 и ингибитора гистондезацетилазы
EA200800700A1 (ru) Новые сульфонилпирролы как ингибиторы гдац (гистондезацетилазы)
AR045317A1 (es) Forma cristalina de agonista dl receptor adrenergico b2
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
EA201291447A1 (ru) Оптически активное производное дибензиламина и способ его получения
ATE340794T1 (de) Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
PE20060681A1 (es) Composicion farmaceutica que comprende un inhibidor de tace en combinacion con un inhibidor de quinasa de src y un inhibidor del her-2
PE20061451A1 (es) Compuestos derivados de diarilsulfona sulfonamidas
EA200602066A1 (ru) Кристаллические полиморфные формы n-[8(2-гидроксибензоил)амино]каприлата натрия
ATE325119T1 (de) 3-substituierte oxindol-beta-3-agonisten
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
WO2007056517A3 (en) Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor
EA200970161A1 (ru) Производные 1-(-d-гликопиранозил)-3-(4-циклопропилфенилметил)-4-галогеноиндола и их применение в качестве ингибиторов sglt
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
EA200700931A1 (ru) Новые производные дикарбоновых кислот
EA200802382A1 (ru) Соли n-гидрокси-3-[4-[[[2-(2-метил-1н-индол-3-ил)этил]амино]метил]фенил]-2е-2-пропенамида
EA200700648A1 (ru) 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги
PE20060820A1 (es) Derivados de 2- (4 - {4- [(3, 5- bis- trifluorometil- bencil) - (2- metil- 2h- tetrazol-5-il)-amino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carbonil}-ciclohexil)-acetamida como inhibidores de la cetp
RU2384573C2 (ru) Пиразол- и фенилпроизводные в качестве ингибиторов ppar
EA200801875A1 (ru) Антагонист cd 80
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130527